Oxamic acid
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].
Product Specifications
CAS Number
[471-47-6]
Product Name Alternative
Oxamidic acid
UNSPSC
12352211
Hazard Statement
H302, H372, H411
Target
Apoptosis; Lactate Dehydrogenase
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/oxamic-acid.html
Purity
99.98
Solubility
H2O : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC(C(O)=O)=O
Molecular Formula
C2H3NO3
Molecular Weight
89.05
Precautions
H302, H372, H411
References & Citations
[1]Xiang J, et al. LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells. Aging (Albany NY) . 2021 Dec 16;13 (24) :25920-25930.|[2]Zhai X, et al. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol Rep. 2013 Dec;30 (6) :2983-91.|[3]Muramatsu H, et al. Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells. Oncol Rep. 2019 Jul;42 (1) :224-230.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Cell Rep. 2025 Apr 9;44 (4) :115545.|Free Radic Biol Med. 2024 Nov 20:225:910-924.|J Adv Res. 2025 May 13:S2090-1232 (25) 00351-0.|J Proteome Res. 2023 Dec 1;22 (12) :3854-3865.|Mol Immunol. 2025 May 9:183:93-103.|Adv Sci (Weinh) . 2024 Jul 9:e2406333.|Adv Sci (Weinh) . 2025 Apr;12 (14) :e2413121.|Adv Sci (Weinh) . 2025 Aug 11:e01041.|Adv Sci (Weinh) . 2025 Jun 5:e06529.|Adv Sci (Weinh) . 2025 Nov 26:e12002.|Biochem Biophys Res Commun. 2025 Sep 8:778:152379.|Biochem Pharmacol. 2025 Jun 23:117073.|Biol Direct. 2025 May 26;20 (1) :64.|bioRxiv. 2025 Apr 3:2025.04.03.647023.|Cancer Immunol Immunother. 2025 Apr 24;74 (6) :180.|Cell Death Differ. 2025 Mar;32 (3) :530-545.|Cell Death Dis. 2025 Mar 20;16 (1) :193.|Cell Discov. 2025 Oct 7;11 (1) :81.|Cell Immunol. 2025 Feb 10:409-410:104929.|Cell Rep. 2024 Aug 30;43 (9) :114686.|Curr Microbiol. 2025 Aug 16;82 (10) :456.|Environ Pollut. 2025 Apr 3:373:126200.|Exp Neurol. 2026 Feb:396:115553.|Food Biosci. 2025 Jun.|Food Chem. 2025 Sep 12:11:100301.|J Anim Sci Biotechnol. 2024 Jun 11;15 (1) :86.|J Autoimmun. 2025 Apr 2:153:103411.|J Cell Commun Signal. 2025 Jul 25;19 (3) :e70037.|J Ginseng Res. 2024 May;48 (3) :298-309.|J Hazard Mater. 2025 Jan 21:488:137310.|J Hazard Mater. 2025 Jun 26:495:139083.|JCI Insight. 2025 Apr 29:e190838.|MedComm (2020) . 2025 Aug 29;6 (9) :e70344.|Nat Commun. 2025 Aug 4;16 (1) :7165.|Neuron. 2025 Jul 23;113 (14) :2280-2296.e8.|Redox Biol. 2024 Jun 20:75:103246.|Redox Biol. 2025 Apr:81:103553.|Research Square Preprint. 2023 Sep 15.|Sci Rep. 2025 Nov 26;15 (1) :42171.|Stem Cell Res Ther. 2025 Oct 1;16 (1) :538.|Theranostics. 2023 Jul 3;13 (11) :3856-3871.|Toxicology. 2025 Jun:514:154109.|University of Minnesota. 2025.|Vet Res. 2025 Apr 30;56 (1) :94.|Virol Sin. 2025 Nov 21:S1995-820X (25) 00161-0.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
E-EL-M3018-01 24 Tests
Mouse AGER (Total Advanced Glycosylation End Product Specific Receptor) ELISA Kit
Ask
View Details E-EL-M3018-02 48 Tests
Mouse AGER (Total Advanced Glycosylation End Product Specific Receptor) ELISA Kit
Ask
View Details E-EL-M3018-03 96 Tests
Mouse AGER (Total Advanced Glycosylation End Product Specific Receptor) ELISA Kit
Ask
View Details 
